Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asuragen, Focus in diagnostics partnership

This article was originally published in Clinica

Executive Summary

Molecular diagnostics specialist Asuragen has granted non-exclusive worldwide rights for its armoured RNA technology to Focus Diagnostics. The deal will see Focus, the Cypress, California-based infectious disease diagnostics subsidiary of Quest Diagnostics, incorporate Asuragen’s technology into its in vitro molecular diagnostics products. Financial terms of the deal were not revealed. According to Asuragen (Austin, Texas), its armoured RNA technology is designed to package RNA or DNA in baceteriophage coat proteins for protection and stabilisation.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042575

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel